[1]
|
Luk, A.J. and Simkin, P.A. (2005) Epidemiology of Hyperuricemia and Gout. The American Journal of Managed Care, 11, S435-S442.
|
[2]
|
Mackenzie, I.S., Ford, I., Nuki, G., Hallas, J., Hawkey, C.J., Webster, J., et al. (2020) Long-Term Cardiovascular Safety of Febuxostat Compared with Allopurinol in Patients with Gout (FAST): A Multicentre, Prospective, Randomised, Open-Label, Non-Inferiority Trial. The Lancet (London, England), 396, 1745-1757.
https://doi.org/10.1016/S0140-6736(20)32234-0
|
[3]
|
Wu, M., Tian, Y., Wang, Q. and Guo, C. (2020) Gout: A Disease Involved with Complicated Immunoinflammatory Responses: A Narrative Review. Clinical Rheumatology, 39, 2849-2859. https://doi.org/10.1007/s10067-020-05090-8
|
[4]
|
Dehlin, M. and Jacobsson, L. (2020) Global Epidemiology of Gout: Prevalence, Incidence, Treatment Patterns and Risk Factors. Nature Reviews Rheumatology, 16, 380-390. https://doi.org/10.1038/s41584-020-0441-1
|
[5]
|
Singh, J.A. and Gaffo, A. (2020) Gout Epidemiology and Comorbidities. Seminars in Arthritis and Rheumatism, 50, S11-S16. https://doi.org/10.1016/j.semarthrit.2020.04.008
|
[6]
|
Liang, J., Jiang, Y., Huang, Y., Song, W., Li, X., Huang, Y., et al. (2020) The Comparison of Dyslipidemia and Serum Uric Acid in Patients with Gout and Asymptomatic Hyperuricemia: A Cross-Sectional Study. Lipids in Health and Disease, 19, 31. https://doi.org/10.1186/s12944-020-1197-y
|
[7]
|
Ayoade, G.O. and Kuti, M.A. (2019) Defining Apolipoprotein B Treatment Targets. Nigerian Journal of Clinical Practice, 22, 355-360.
|
[8]
|
Neogi, T., Jansen, T.L., Dalbeth, N., Fransen, J., Schumacher, H.R., Berendsen, D., et al. (2015) 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis & Rheumatology (Hoboken, NJ), 67, 2557-2568. https://doi.org/10.1136/annrheumdis-2015-208237
|
[9]
|
Kuo, C.F., Grainge, M.J., Zhang, W. and Doherty, M. (2015) Global Epidemiology of Gout: Prevalence, Incidence and Risk Factors. Nature Reviews Rheumatology, 11, 649-662. https://doi.org/10.1038/nrrheum.2015.91
|
[10]
|
Primatesta, P., Plana, E. and Rothenbacher, D. (2011) Gout Treatment and Comorbidities: A Retrospective Cohort Study in a Large US Managed Care Population. BMC Musculoskeletal Disorders, 12, 103.
https://doi.org/10.1186/1471-2474-12-103
|
[11]
|
Zheng, X., Gong, L., Luo, R., Chen, H., Peng, B., Ren, W., et al. (2017) Serum Uric Acid and Non-Alcoholic Fatty Liver Disease in Non-Obesity Chinese Adults. Lipids in Health and Disease, 16, 202.
https://doi.org/10.1186/s12944-017-0531-5
|
[12]
|
Ali, N., Rahman, S. and Islam, S. (2019) The Relationship between Serum Uric Acid and Lipid Profile in Bangladeshi Adults. BMC Cardiovascular Disorders, 19, Article No. 42. https://doi.org/10.1186/s12872-019-1026-2
|
[13]
|
Tao, M., Pi, X., Ma, X., Shi, Y., Zhang, Y., Gu, H., et al. (2019) Relationship between Serum Uric Acid and Clustering of Cardiovascular Disease Risk Factors and Renal Disorders among Shanghai Population: A Multicentre and Cross-Sectional Study. BMJ Open, 9, e025453. https://doi.org/10.1136/bmjopen-2018-025453
|
[14]
|
Johannesen, C.D.L., Mortensen, M.B., Langsted, A. and Nordestgaard, B.G. (2021) Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology, 77, 1439-1450. https://doi.org/10.1016/j.jacc.2021.01.027
|
[15]
|
Sniderman, A.D., Thanassoulis, G., Glavinovic, T., Navar, A.M., Pencina, M., Catapano, A., et al. (2019) Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology, 4, 1287-1295.
https://doi.org/10.1001/jamacardio.2019.3780
|
[16]
|
Benn, M., Nordestgaard, B.G., Jensen, G.B. and Tybjaerg-Hansen, A. (2007) Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B: The Copenhagen City Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 661-670. https://doi.org/10.1161/01.ATV.0000255580.73689.8e
|
[17]
|
Zhu, Y., Hu, Y., Huang, T., Zhang, Y., Li, Z., Luo, C., et al. (2014) High Uric Acid Directly Inhibits Insulin Signalling and Induces Insulin Resistance. Biochemical and Biophysical Research Communications, 447, 707-714.
https://doi.org/10.1016/j.bbrc.2014.04.080
|
[18]
|
DeFronzo, R.A. and Ferrannini, E. (1991) Insulin Resistance. A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease. Diabetes Care, 14, 173-194.
https://doi.org/10.2337/diacare.14.3.173
|
[19]
|
Fraile, J.M., Torres, R.J., de Miguel, M.E., Martínez, P., Lundelin, K.J., Vázquez, J.J., et al. (2010) Metabolic Syndrome Characteristics in Gout Patients. Nucleosides, Nucleotides & Nucleic Acids, 29, 325-329.
https://doi.org/10.1080/15257771003738709
|